drugset / Trial / NCT05891366
Single Ascending Dose Study of WAL0921 in Healthy Subjects
RandomizedParallel-groupTriple-blindBasic science
Summary
This is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of WAL0921 in healthy subjects.
Timeline
- Start
- 2023-05-31
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WAL0921 | Unknown | — | Intravenous |
Indications
No indication recorded.